Viridian Therapeutics, Inc./DE Net Income (Loss) Available to Common Stockholders, Basic
Viridian Therapeutics, Inc./DE (VRDN) reported Net Income (Loss) Available to Common Stockholders, Basic of -$25.69 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-13.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-05-13
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$25.69M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$28.95M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$14.04M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$17.96M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for fiscal 2021 was -$79.41M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for fiscal 2020 was -$110.72M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for fiscal 2019 was -$41.87M.
- Viridian Therapeutics, Inc./DE net income (loss) available to common stockholders, basic for fiscal 2018 was -$32.70M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$25.69M 10-Q · filed 2022-05-13 | -$54.64M derived: sum of 2 quarters · filed 2022-05-13 | -$68.68M derived: sum of 3 quarters · filed 2022-05-13 | -$86.65M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2021-12-31 | -$28.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$42.99M derived: sum of 2 quarters · filed 2022-03-11 | -$60.95M derived: sum of 3 quarters · filed 2022-03-11 | -$79.41M 10-K · filed 2022-03-11 | |
| 2021-09-30 | -$14.04M 10-Q · filed 2021-11-05 | -$32.01M derived: sum of 2 quarters · filed 2021-11-05 | -$50.47M 10-Q · filed 2021-11-05 | -$141.21M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2021-06-30 | -$17.96M 10-Q · filed 2021-08-12 | -$36.42M 10-Q · filed 2021-08-12 | -$127.17M derived: sum of 3 quarters · filed 2022-05-13 | -$132.66M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2021-03-31 | -$18.46M 10-Q · filed 2022-05-13 | -$109.20M derived: sum of 2 quarters · filed 2022-05-13 | -$114.70M derived: sum of 3 quarters · filed 2022-05-13 | -$121.13M derived: sum of 4 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$90.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | -$96.24M derived: sum of 2 quarters · filed 2022-03-11 | -$102.67M derived: sum of 3 quarters · filed 2022-03-11 | -$110.72M 10-K · filed 2022-03-11 | |
| 2020-09-30 | -$5.49M 10-Q · filed 2021-11-05 | -$11.93M derived: sum of 2 quarters · filed 2021-11-05 | -$19.97M 10-Q · filed 2021-11-05 | -$30.09M derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | -$6.43M 10-Q · filed 2021-08-12 | -$14.48M 10-Q · filed 2021-08-12 | -$24.60M derived: sum of 3 quarters · filed 2021-08-12 | -$35.83M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | -$8.04M 10-Q · filed 2021-05-07 | -$18.16M derived: sum of 2 quarters · filed 2021-05-07 | -$29.39M derived: sum of 3 quarters · filed 2021-05-07 | -$38.29M derived: sum of 4 quarters · filed 2021-05-07 | |
| 2019-12-31 | -$10.12M 10-K · filed 2020-03-13 | -$21.35M derived: sum of 2 quarters · filed 2020-11-12 | -$30.25M derived: sum of 3 quarters · filed 2020-11-12 | -$41.87M 10-K · filed 2021-03-26 | |
| 2019-09-30 | -$11.23M 10-Q · filed 2020-11-12 | -$20.13M derived: sum of 2 quarters · filed 2020-11-12 | -$31.75M 10-Q · filed 2020-11-12 | -$42.07M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$8.90M 10-Q · filed 2020-08-05 | -$20.52M 10-Q · filed 2020-08-05 | -$30.84M derived: sum of 3 quarters · filed 2020-08-05 | -$39.86M derived: sum of 4 quarters · filed 2020-08-05 | |
| 2019-03-31 | -$11.63M 10-Q · filed 2020-05-08 | -$21.94M derived: sum of 2 quarters · filed 2020-05-08 | -$30.96M derived: sum of 3 quarters · filed 2020-05-08 | -$39.67M derived: sum of 4 quarters · filed 2020-05-08 | |
| 2018-12-31 | -$10.31M 10-K · filed 2020-03-13 | -$10.32M 10-K · filed 2019-03-14 | -$19.34M derived: sum of 2 quarters · filed 2020-03-13 | -$28.05M derived: sum of 3 quarters · filed 2020-03-13 | -$32.70M 10-K · filed 2020-03-13 |
| 2018-09-30 | -$9.02M 10-K · filed 2020-03-13 | -$9.01M 10-Q · filed 2018-11-07 | -$17.73M derived: sum of 2 quarters · filed 2020-03-13 | -$22.39M 10-Q · filed 2019-11-08 | -$28.78M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-06-30 | -$8.71M 10-K · filed 2020-03-13 | -$8.71M 10-Q · filed 2018-08-08 | -$13.38M 10-Q · filed 2018-08-08 | -$19.76M derived: sum of 3 quarters · filed 2020-03-13 | -$25.59M derived: sum of 4 quarters · filed 2020-03-13 |
| 2018-03-31 | -$4.66M 10-K · filed 2020-03-13 | -$11.05M derived: sum of 2 quarters · filed 2020-03-13 | -$16.88M derived: sum of 3 quarters · filed 2020-03-13 | -$24.19M derived: sum of 4 quarters · filed 2020-03-13 | |
| 2017-12-31 | -$6.39M 10-K · filed 2019-03-14 | -$12.22M derived: sum of 2 quarters · filed 2019-03-14 | -$19.53M derived: sum of 3 quarters · filed 2019-03-14 | -$26.52M 10-K · filed 2019-03-14 | |
| 2017-09-30 | -$5.83M 10-K · filed 2019-03-14 | -$13.15M derived: sum of 2 quarters · filed 2019-03-14 | -$20.13M 10-Q · filed 2018-11-07 | -$26.12M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2017-06-30 | -$7.31M 10-K · filed 2019-03-14 | -$14.30M 10-Q · filed 2018-08-08 | -$20.28M derived: sum of 3 quarters · filed 2019-03-14 | -$24.45M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2017-03-31 | -$6.99M 10-K · filed 2019-03-14 | -$12.97M derived: sum of 2 quarters · filed 2019-03-14 | -$17.14M derived: sum of 3 quarters · filed 2019-03-14 | -$20.67M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2016-12-31 | -$5.99M 10-K · filed 2018-03-15 | -$10.15M derived: sum of 2 quarters · filed 2018-03-15 | -$13.69M derived: sum of 3 quarters · filed 2018-03-15 | -$17.32M 10-K · filed 2018-03-15 | |
| 2016-09-30 | -$4.17M 10-K · filed 2018-03-15 | -$7.70M derived: sum of 2 quarters · filed 2018-03-15 | -$11.34M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | -$3.54M 10-K · filed 2018-03-15 | -$7.17M 10-Q · filed 2017-08-11 | |||
| 2016-03-31 | -$3.63M 10-K · filed 2018-03-15 | ||||
| 2014-12-31 | -$2.26M derived: 10-K 12 month − 10-K 9 month · filed 2015-03-27 | -$3.90M derived: sum of 2 quarters · filed 2015-03-27 | -$7.18M derived: sum of 3 quarters · filed 2015-03-27 | -$7.89M 10-K · filed 2015-03-27 | |
| 2014-09-30 | -$1.64M 10-K · filed 2015-03-27 | -$4.93M derived: sum of 2 quarters · filed 2015-03-27 | -$5.63M 10-K · filed 2015-03-27 | -$5.88M derived: sum of 4 quarters · filed 2015-03-27 | |
| 2014-06-30 | -$3.29M 10-K · filed 2015-03-27 | -$4.00M 10-K · filed 2015-03-27 | -$4.24M derived: sum of 3 quarters · filed 2015-03-27 | -$5.18M derived: sum of 4 quarters · filed 2015-03-27 | |
| 2014-03-31 | -$706.00K derived: 10-K 12 month − 3 quarters · filed 2015-03-27 | -$955.00K derived: sum of 2 quarters · filed 2015-03-27 | -$1.90M derived: sum of 3 quarters · filed 2015-03-27 | -$2.52M derived: sum of 4 quarters · filed 2015-03-27 | |
| 2013-12-31 | -$249.00K derived: 10-K 12 month − 10-K 9 month · filed 2015-03-27 | -$1.19M derived: sum of 2 quarters · filed 2015-03-27 | -$1.82M derived: sum of 3 quarters · filed 2015-03-27 | -$2.44M 10-K · filed 2015-03-27 | |
| 2013-09-30 | -$940.00K 10-K · filed 2015-03-27 | -$1.57M derived: sum of 2 quarters · filed 2015-03-27 | -$2.20M 10-K · filed 2015-03-27 | ||
| 2013-06-30 | -$630.00K 10-K · filed 2015-03-27 | -$1.26M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |